Literature DB >> 15276413

Distributions and chemical forms of arsenic after intravenous administration of dimethylarsinic and monomethylarsonic acids to rats.

Kazuo T Suzuki1, Akio Katagiri, Yoko Sakuma, Yasumitsu Ogra, Masayoshi Ohmichi.   

Abstract

The observed toxicity of arsenic is highly dependent on animal species and differences in metabolism. Rats are one of the most tolerant species, and the metabolic pathway is quite different in some aspects from those of other mammals. The distinct metabolic pathway including the preferential accumulation in red blood cells (RBCs) has been explained, whereby allowing an effective use of rats as an animal model for the arsenic metabolism. In the present study, distributions of arsenic among organs/tissues/body fluids and their chemical forms were studied after intravenous injection of arsenic in the forms of dimethylarsinic (DMA(V)) and monomethylarsonic acids (MMA(V)) to rats. DMA(V) and MMA(V) were mostly excreted into urine immediately after the injection as the intact forms, and both forms were taken up less effectively by organs/tissues than arsenite. The methylated arsenics distributed in organs/tissues were excreted directly into urine and excreted before being redistributed in RBCs. DMA(V) and MMA(V) taken up by the liver were transformed to metabolites not yet identified, accumulated transiently in the liver, and then they disappeared from the liver. The unidentified metabolites were assumed to be transformed from dimethylarsinic acid (DMA(III)) following the consecutive metabolic reactions [MMA(V) --> monomethylarsonous acid (MMA(III)) --> DMA(V) --> DMA(III)]. The unidentified metabolites were excreted not into the bile but into the bloodstream. Injections of DMA(V) and MMA(V) induced a biliary excretion of arsenic but only at 0.2-0.3% of the dose, the arsenic in the bile being their intact free forms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276413     DOI: 10.1016/j.taap.2003.10.029

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  9 in total

1.  Tissue dosimetry, metabolism and excretion of pentavalent and trivalent monomethylated arsenic in mice after oral administration.

Authors:  Michael F Hughes; Vicenta Devesa; Blakely M Adair; Miroslav Styblo; Elaina M Kenyon; David J Thomas
Journal:  Toxicol Appl Pharmacol       Date:  2005-10-15       Impact factor: 4.219

2.  shRNA silencing of AS3MT expression minimizes arsenic methylation capacity of HepG2 cells.

Authors:  Zuzana Drobna; Weibing Xing; David J Thomas; Miroslav Stýblo
Journal:  Chem Res Toxicol       Date:  2006-07       Impact factor: 3.739

3.  Speciation analysis of arsenic in biological matrices by automated hydride generation-cryotrapping-atomic absorption spectrometry with multiple microflame quartz tube atomizer (multiatomizer).

Authors:  Araceli Hernández-Zavala; Tomáš Matoušek; Zuzana Drobná; David S Paul; Felecia Walton; Blakely M Adair; Dědina Jiří; David J Thomas; Miroslav Stýblo
Journal:  J Anal At Spectrom       Date:  2008       Impact factor: 4.023

4.  Tissue dosimetry, metabolism and excretion of pentavalent and trivalent dimethylated arsenic in mice after oral administration.

Authors:  Michael F Hughes; Vicenta Devesa; Blakely M Adair; Sean D Conklin; John T Creed; Miroslav Styblo; Elaina M Kenyon; David J Thomas
Journal:  Toxicol Appl Pharmacol       Date:  2007-10-22       Impact factor: 4.219

5.  Interaction effects of lead on bioavailability and pharmacokinetics of arsenic in the rat.

Authors:  Violet Diacomanolis; Barry N Noller; Jack C Ng
Journal:  Environ Geochem Health       Date:  2013-06-01       Impact factor: 4.609

Review 6.  Metabolism, toxicity and anticancer activities of arsenic compounds.

Authors:  Islam Khairul; Qian Qian Wang; Yu Han Jiang; Chao Wang; Hua Naranmandura
Journal:  Oncotarget       Date:  2017-04-04

7.  Study on the Absorption of Arsenic Species in Realgar Based on the Form and Valence.

Authors:  Mingyi Sun; Yaolei Li; Ying Wang; Huimin Wu; Jing Liu; Longtai You; HuLinyue Peng; Huating Huang; Hongyu Jin; Xiaoxu Dong; Changhai Qu; Xingbin Yin; Jian Ni
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-23       Impact factor: 2.650

Review 8.  Realgar (α-As4S4) Treats Myelodysplastic Syndromes through Reducing DNA Hypermethylation.

Authors:  Miao Zhang; Jia-Yi Zhang; Ming-Qian Sun; Peng Lu; Jian-Xun Liu
Journal:  Chin J Integr Med       Date:  2020-05-16       Impact factor: 1.978

9.  The Investigation of Unexpected Arsenic Compounds Observed in Routine Biological Monitoring Urinary Speciation Analysis.

Authors:  Elizabeth Leese; Malcolm Clench; Jackie Morton; Philip H E Gardiner; Vikki A Carolan
Journal:  Toxics       Date:  2017-05-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.